Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22430280 | 1.00 | TERT (0.37) | TERTTSHRSMN1; SMN2MAPTCA1 | |
| SCHEMBL1036565 | 0.91 | — | — | |
| SCHEMBL20030558 | 0.83 | TSHR (0.36) | TSHRSMN1; SMN2MAPT | |
| SCHEMBL1674375 | 0.81 | SMN1; SMN2 (0.52) | TERTTSHRSMN1; SMN2MAPT | |
| SCHEMBL20960419 | 0.79 | TERT (0.35) | TERTCA1CA2 | |
| SCHEMBL25130121 | 0.78 | KDM4E (0.34) | TSHRSMN1; SMN2MAPT | |
| SCHEMBL30080900 | 0.78 | TSHR (0.30) | TSHRSMN1; SMN2MAPT | |
| SCHEMBL26349405 | 0.78 | CA1 (0.34) | TSHRSMN1; SMN2MAPTCA1CA2 | |
| SCHEMBL22783602 | 0.77 | TERT (0.41) | TERTCA1CA2 | |
| SCHEMBL31120959 | 0.76 | KDM4E (0.36) | TSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071526-A | PVRIG binding molecules and uses thereof | 广东菲鹏制药股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| WO-2025242900-A1 | COACERVATE-FORMING REAGENTS AND METHODS | PARTITIONBIO LTD (GB) | 2025-11-27 | — | — | WO | claimed |
| EP-4642808-A2 | ANTI-ROR-2 ANTIBODIES AND METHODS OF USE | The Regents of the University of California (US) | 2025-11-05 | — | — | EP | claimed |
| US-20250231186-A1 | COUPLING ASSAY FOR T CELL SPECIFICITY (CATS) AND METHOD OF ITS USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-07-17 | — | — | US | claimed |
| EP-4582442-A2 | TNFR2 AGONISTS WITH IMPROVED STABILITY | Universität Stuttgart (DE) | 2025-07-09 | — | — | EP | claimed |
| EP-3986920-B1 | TNFR2 AGONISTS WITH IMPROVED STABILITY | UNIV STUTTGART (DE) | 2025-04-16 | — | — | EP | claimed |
| WO-2025061991-A2 | DEVICE AND METHOD FOR LASER TREATMENT OF THE RETINA OF AN EYE WITH A LASER POWER ABOVE THE EYE SAFETY THRESHOLD | OD-OS MACUTHERM GMBH (DE) | 2025-03-27 | — | — | WO | claimed |
| EP-3478162-B1 | GRANZYME B DIRECTED IMAGING AND THERAPY | MASSACHUSETTS GEN HOSPITAL (US) | 2025-03-19 | — | — | EP | claimed |
| CN-119552220-A | Polypeptide with cell adhesion effect and application thereof | 陕西未来多肽生物科技有限公司 | 2025-03-04 | — | — | CN | claimed |
| US-20240368295-A1 | ANTI-BCMA ANTIBODIES AND TREATMENT METHODS | SUTRO BIOPHARMA, INC. | 2024-11-07 | — | — | US | claimed |
| CN-115175708-A | Method for site-specific modification of antibodies | 奥兰诺医药公司 | 2022-10-11 | — | — | CN | claimed |
| US-20220267410-A1 | TNFR2 Agonists with Improved Stability | Universität Stuttgart (DE) | 2022-08-25 | — | — | US | claimed |
| CN-114807153-A | Multiple CpG oligodeoxynucleotide with immune stimulation activity and application thereof | 南京吉盛澳玛生物医药有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-20220233658-A1 | RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE | Ab biosciences inc (US) | 2022-07-28 | — | — | US | claimed |
| US-20220204592-A1 | HA BINDING AGENTS | Visterra, Inc. | 2022-06-30 | — | — | US | claimed |
| EP-4003392-A1 | PEPTIDES FOR TREATING NON-EXUDATIVE MACULAR DEGENERATION AND OTHER DISORDERS OF THE EYE | Allegro Pharmaceuticals, LLC (US) | 2022-06-01 | — | — | EP | claimed |
| CN-114516914-A | Antibody against N-terminal pro-brain natriuretic peptide, and reagent and kit for detecting N-terminal pro-brain natriuretic peptide | 东莞市朋志生物科技有限公司 | 2022-05-20 | — | — | CN | claimed |
| EP-3986920-A1 | TNFR2 AGONISTS WITH IMPROVED STABILITY | Universität Stuttgart (DE) | 2022-04-27 | — | — | EP | claimed |
| US-11304994-B2 | Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use | AB BIOSCIENCES, INC. (US) | 2022-04-19 | — | — | US | claimed |
| WO-2022051555-A2 | SOLUBLE ALKALINE PHOSPHATASE CONSTRUCTS AND EXPRESSION VECTORS INCLUDING A POLYNUCLEOTIDE ENCODING FOR SOLUBLE ALKALINE PHOSPHATASE CONSTRUCTS | RAMPART BIOSCIENCE, INC. (US) | 2022-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204592-A1 | HA BINDING AGENTS | HAVCR2, CD44, CD2BP2 | TERT 4392/4885TSHR 1892/4885SMN1; SMN2 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.